| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:36372265 | IVR | 1 ppm | 1 ppm | Changes in brain morphology | Neurological endocrine-mediated perturbations |
| IVR | 500 - 1000 ppm | 500 - 1000 ppm | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Hypertrophy in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 500 - 1000 ppm | 500 - 1000 ppm | Hypertrophy in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Increase in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 500 - 1000 ppm | 500 - 1000 ppm | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Decreased body weights in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Decreased rT3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 500 - 1000 ppm | 500 - 1000 ppm | Increase in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 500 - 1000 ppm | 500 - 1000 ppm | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 500 - 1000 ppm | 500 - 1000 ppm | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 500 - 1000 ppm | 500 - 1000 ppm | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 500 - 1000 ppm | 500 - 1000 ppm | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 500 - 1000 ppm | 500 - 1000 ppm | Decreased body weights | Metabolic endocrine-mediated pe | |
| PMID:38499550 | IVR | 5 ppm | 5 ppm | Hypertrophy in thyroid gland | Metabolic endocrine-mediated perturbations |
| IVR | 5 ppm | 5 ppm | Hyperplasia in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 5 ppm | 5 ppm | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| PMID:39496387 | IVR | 1 - 15 ppm | 1 - 15 ppm | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 1 - 15 ppm | 1 - 15 ppm | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 15 ppm | 1 - 15 ppm | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 1 - 15 ppm | 1 - 15 ppm | Gait abnormality | Developmental endocrine-mediated perturbations | |
| IVR | 1 - 15 ppm | 1 - 15 ppm | Increase in T4 levels | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.